Email ID
Password
Scrip   
Novo Nordisk's diabetes drug liraglutide stumbles on thyroid cancer concerns
03 April 2009
Sue Sutter

Novo Nordisk's GLP-1 analogue Victoza (liraglutide) injection does not present an excessive cardiovascular risk, but questions about thyroid carcinogenicity may preclude approval of the agent for type 2 diabetes, the US FDA's outside experts have said.
The endocrinologic and metabolic drugs advisory...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36